Bolivia Technical Dossier: Section 2.4 Element Breakdown and Common Gaps
Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
Section 2.4 of the Manual is the core provision governing the technical dossier in Bolivia. It requires the file to contain the following elements: parts and components; certificate of analysis or design verification and validation report; shelf life; storage conditions; international nomenclature codes (ECRI, GMDN or equivalent); lot number coding; risk level; summary of instructions for use; sterilization method; and disposal method. In addition, Section 2.4.8 requires clinical study evidence for medium-to-high risk and new products. GRZAN’s assessment is that three of these ten elements, namely the international nomenclature codes, lot number coding and the disposal method, do not routinely appear in the standard technical documentation prepared in China, and they are the most frequent gaps in first-round submissions. Companies should not assume that a dossier accepted in other markets can be reused as-is: the Bolivian element list is a distinct checklist, and reviewers screen against it item by item. Building a cross-reference table against all ten elements before submission is the most reliable way to avoid the observation cycle that follows an incomplete first filing. A dossier that is complete on nine elements but silent on the tenth is treated as incomplete, so the checklist discipline applies to every element with equal weight. Companies converting an existing dossier for Bolivia should budget translation time for these elements specifically, since they are the items least likely to have Spanish text prepared in advance.
2. Legal basis
| Regulation | Reference number | Publication date | Provision |
|---|---|---|---|
| Manual para Registro Sanitario de Dispositivos Médicos | Resolución Ministerial N° 010 | Current version as published on the AGEMED website | Section 2.4 |
| Manual para Registro Sanitario de Dispositivos Médicos | Resolución Ministerial N° 010 | Current version as published on the AGEMED website | Section 2.4.7 |
| Manual para Registro Sanitario de Dispositivos Médicos | Resolución Ministerial N° 010 | Current version as published on the AGEMED website | Section 2.4.8 |
| Manual para Registro Sanitario de Dispositivos Médicos | Resolución Ministerial N° 010 | Current version as published on the AGEMED website | Section 2.9 |
3. Expert insights
Insight one: the certificate of analysis or design verification and validation report is an either-or structure. The wording of Section 2.4 allows the requirement to be satisfied either by a certificate of analysis of the finished product or by a design verification and validation report. For sterile consumables, the certificate of analysis route is more direct, because each batch can be characterized by measurable release parameters. For active devices, the design verification and validation report fits better, since the safety of an electromedical product rests on its design controls rather than on batch release testing. Choosing the wrong route leads to a mismatch between the documents and the nature of the product, which reviewers typically flag as an observation rather than reject outright, but the correction still costs a review cycle. Where a product has characteristics of both categories, the stronger documentary route should be chosen and the choice explained in the dossier, so that the reviewer sees a deliberate decision rather than an omission.
Insight two: the international nomenclature code is a mandatory field, not an optional refinement. The Manual expressly accepts ECRI, GMDN or equivalent codes. GRZAN recommends completing the GMDN code search and matching early in the document preparation phase, because the code simultaneously affects the Spanish rendering of the product name and the identification of the product in subsequent periodic reporting. A code selected late in the process tends to conflict with the name already used on labels and in the application form, forcing last-minute harmonization across multiple documents. Early alignment keeps the product identity consistent from the application form through to post-market records. The code should also be recorded in internal systems, since post-market reports and periodic submissions will refer back to the same identifier throughout the life of the registration.
Insight three: the disposal method reflects regulatory attention to the full product life cycle. This element is not usually listed as a separate item in registration dossiers prepared in China. Bolivia writes it into the technical documentation requirement, which shows that the review perspective extends to the post-use stage of the product. Companies must prepare a Spanish description consistent with the local medical waste management context, covering how used devices, sharps and packaging are segregated and destroyed. A text copied from an environmental datasheet in another jurisdiction rarely matches Bolivian waste handling terminology and will likely draw a request for revision. The description should name the waste category, the segregation step and the final treatment route in terms familiar to hospital waste managers.
4. Practical recommendations
- Build a comparison table against the ten elements of Section 2.4, marking the source document for each item, and use it as the internal release checklist for the dossier before submission.
- Complete the matching of GMDN or another international nomenclature code early, and align the code and the product name with the Spanish label wording.
- Prepare a dedicated Spanish page for the disposal method, and do not expect a usable text to come from a literal translation of the Chinese instructions for use.
- Verify the shelf life and storage conditions are consistent across the certificate of analysis, the label and the summary of instructions for use, since reviewers cross-check these figures across documents.
5. Verification checklist
- □ All ten elements are covered item by item with corresponding documents
- □ The certificate of analysis or design verification route matches the nature of the product
- □ The international nomenclature code, GMDN or equivalent, has been determined and matches the label
- □ The lot number coding rules have been described in the dossier
- □ A dedicated Spanish page exists for the disposal method
Regulatory information verified as of October 29, 2026.
GRZAN provides registration support in Bolivia for manufacturers, importers and authorized representatives, covering technical dossier assembly, nomenclature coding, Spanish documentation and regulatory correspondence. For assistance with Section 2.4 requirements and the full registration process, contact info@grzanglobal.com. Support runs from element mapping through final Spanish documentation.
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us